Skip to main content

Table 2 Baseline characteristics of the 9 patients with hereditary hemorrhagic telangiectasia (HHT) with ascertained SarsCov-2 infection

From: Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy

ID

Gender

Age

Residency region (province)

HHT type

PCR-based molecular diagnosis on swab sample

Nasopharyngeal/oropharyngeal swab

Serol. test

4

F

41

Lombardy (Bergamo)

HHT2

Apparently Negative, but Molecular test was performed three months after symptom onset

Nasal

Pos

20

M

46

Lombardy (Bergamo)

HHT2

Positive

Nasal

Pos

22

M

44

Lombardy (Bergamo)

HHT2

Positive

Nasal

Pos

24

M

57

Liguria (Savona)

HHT2

Positive

Nasal/Oral

Pos

34

F

38

Lombardy (Bergamo)

HHT1

Molecular test never performeda

/

Pos

39

F

35

Lombardy (Cremona)

HHT1

Apparently Negative, but molecular test was performed two months after symptom onset

Nasal/Oral

Pos

49

M

41

Lombardy (Bergamo)

HHT2

Apparently Negative, but molecular test was performed two months after symptom onset

Nasal

Pos

66

M

49

Lombardy (Bergamo)

HHT2

Molecular test never performeda

/

Pos

119

M

65

Lombardy (Brescia)

HHT1

Positive

Nasal/Oral

Pos

  1. HHT1 hereditary hemorrhagic telangiectasia type 1, HHT2 hereditary hemorrhagic telangiectasia type 2, PCR polymerase chain reaction
  2. aSymptom onset occurring before lockdown/pandemic declaration, when routinely molecular assay on swab sample was not established